Cargando…

Muscarinic Receptor Agonists and Antagonists

A comprehensive review of pharmacological and medical aspects of the muscarinic class of acetylcholine agonists and antagonists is presented. The therapeutic benefits of achieving receptor subtype selectivity are outlined and applications in the treatment of Alzheimer’s disease are discussed. A sele...

Descripción completa

Detalles Bibliográficos
Autores principales:	Broadley, Kenneth J., Kelly, David R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2001
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236374/ http://dx.doi.org/10.3390/60300142

Ejemplares similares

Multitargeting nature of muscarinic orthosteric agonists and antagonists
por: Myslivecek, Jaromir
Publicado: (2022)

Investigating the Unbinding of Muscarinic Antagonists from the Muscarinic 3 Receptor
por: Buigues, Pedro J., et al.
Publicado: (2023)

The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease()
por: Dale, Philippa R, et al.
Publicado: (2014)

Muscarinic Receptors and Their Antagonists in COPD: Anti-Inflammatory and Antiremodeling Effects
por: Karakiulakis, George, et al.
Publicado: (2012)

The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review
por: Calzetta, Luigino, et al.
Publicado: (2021)

The muscarinic antagonists scopolamine and atropine are competitive antagonists at 5-HT(3) receptors
por: Lochner, Martin, et al.
Publicado: (2016)

Novel long‐acting antagonists of muscarinic ACh receptors
por: Randáková, Alena, et al.
Publicado: (2018)

Effects of (a Combination of) the Beta(2)-Adrenoceptor Agonist Indacaterol and the Muscarinic Receptor Antagonist Glycopyrrolate on Intrapulmonary Airway Constriction
por: Maarsingh, Harm, et al.
Publicado: (2021)

The Bronchoprotective Effects of Dual Pharmacology, Muscarinic Receptor Antagonist and β(2) Adrenergic Receptor Agonist Navafenterol in Human Small Airways
por: Jude, Joseph Antony, et al.
Publicado: (2023)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Muscarinic receptor antagonists and airway inflammation: A systematic review on pharmacological models
por: Calzetta, Luigino, et al.
Publicado: (2022)

Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma
por: Aalbers, René, et al.
Publicado: (2017)

Negative cooperativity in binding of muscarinic receptor agonists and GDP as a measure of agonist efficacy
por: Jakubík, J, et al.
Publicado: (2011)

Development of selective agonists and antagonists of P2Y receptors
por: Jacobson, Kenneth A., et al.
Publicado: (2008)

Structure of the human M(2) muscarinic acetylcholine receptor bound to an antagonist
por: Haga, Kazuko, et al.
Publicado: (2012)

Discovery of new muscarinic acetylcholine receptor antagonists from Scopolia tangutica
por: Du, Nana, et al.
Publicado: (2017)

Involvement of Ca(2+) Signaling in the Synergistic Effects between Muscarinic Receptor Antagonists and β(2)-Adrenoceptor Agonists in Airway Smooth Muscle
por: Fukunaga, Kentaro, et al.
Publicado: (2016)

Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists
por: Liu, Hongtao, et al.
Publicado: (2018)

Non-Peptide Agonists and Antagonists of the Prokineticin Receptors
por: Lattanzi, Roberta, et al.
Publicado: (2022)

Muscarinic Receptors Associated with Cancer
por: Calaf, Gloria M., et al.
Publicado: (2022)

Early to late sparing of radiation damage to the parotid gland by adrenergic and muscarinic receptor agonists
por: Coppes, R P, et al.
Publicado: (2001)

Structural insights into the subtype-selective antagonist binding to the M2 muscarinic receptor
por: Suno, Ryoji, et al.
Publicado: (2018)

Unbinding Kinetics of Muscarinic M3 Receptor Antagonists Explained by Metadynamics Simulations
por: Galvani, Francesca, et al.
Publicado: (2023)

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
por: Yamada, Hideyasu, et al.
Publicado: (2018)

DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo
por: Thompson, Karen J., et al.
Publicado: (2018)

Bis-Quinolinium Cyclophane Blockers of SK Potassium Channels Are Antagonists of M3 Muscarinic Acetylcholine Receptors
por: Bugay, Vladislav, et al.
Publicado: (2020)

Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?
por: Busse, William W., et al.
Publicado: (2016)

Allosteric Modulation of Muscarinic Acetylcholine Receptors
por: Jakubík, Jan, et al.
Publicado: (2010)

Muscarinic Receptor Signaling in Colon Cancer
por: von Rosenvinge, Erik C., et al.
Publicado: (2011)

Molecular properties of muscarinic acetylcholine receptors
por: HAGA, Tatsuya
Publicado: (2013)

Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium
por: Hamelmann, Eckard
Publicado: (2018)

Muscarinic receptor oligomerization
por: Marsango, Sara, et al.
Publicado: (2018)

Muscarinic receptor signaling in the pathophysiology of asthma and COPD
por: Gosens, Reinoud, et al.
Publicado: (2006)

Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD
por: D’Urzo, Anthony D, et al.
Publicado: (2018)

Long-acting muscarinic antagonists for the treatment of asthma in children—a new kid in town
por: Hamelmann, Eckard
Publicado: (2018)

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
por: Ora, Josuel, et al.
Publicado: (2020)

Dynamic Regulation of Quaternary Organization of the M(1) Muscarinic Receptor by Subtype-selective Antagonist Drugs
por: Pediani, John D., et al.
Publicado: (2016)

FRET-Based Detection of M(1) Muscarinic Acetylcholine Receptor Activation by Orthosteric and Allosteric Agonists
por: Markovic, Danijela, et al.
Publicado: (2012)

A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β(2)-Agonist (LABA) Combinations in COPD
por: Sion, Katya Y. J., et al.
Publicado: (2017)

Current Advances in Allosteric Modulation of Muscarinic Receptors
por: Jakubik, Jan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0mbubrjsvtc1t33o3vl5uaf2v5